Welcome to our dedicated page for Cellectis news (Ticker: CLLS), a resource for investors and traders seeking the latest updates and insights on Cellectis stock.
Cellectis S.A. (NASDAQ: CLLS) is a clinical-stage biopharmaceutical leader developing groundbreaking allogeneic CAR-T therapies through precision gene-editing technologies. This page provides investors and industry professionals with essential updates on the company’s clinical trials, regulatory milestones, and strategic developments.
Access real-time announcements including FDA submissions, partnership agreements, and research breakthroughs. Our curated collection features press releases on TALEN®-engineered therapies, hematopoietic stem cell advancements, and financial results – all critical for evaluating this innovator in off-the-shelf cancer treatments.
Key updates cover three focus areas: clinical trial phases for UCART candidates, intellectual property developments, and collaborative research initiatives. Bookmark this page to monitor progress in scalable cancer immunotherapies and maintain informed perspectives on Cellectis’ position within the competitive gene-editing landscape.
Cellectis (NASDAQ: CLLS) reported Q3 2025 results and a business update on Nov 7, 2025. Key clinical highlights: lasme-cel (UCART22) Phase 1 P2 ORR 68% (n=22), RP2D ORR 83% (n=12) and 100% in target Phase 2 population (n=9); median OS 14.8 months in MRD-negative CR/CRi patients. eti-cel (UCART20x22) preliminary ORR 86% and CR 57% (n=7); full Phase 1 dataset expected in 2026 and an ASH 2025 poster on Dec 7.
Finance: consolidated cash, cash equivalents and fixed-term deposits of $225M as of Sept 30, 2025 (runway into H2 2027); nine-month revenue $67.4M (vs $34.1M prior year); consolidated net loss attributable to shareholders $41.3M for nine months. Servier arbitration decision expected on or before Dec 15, 2025.
Cellectis (Euronext Growth: CLLS) published its monthly report on share capital and voting rights as of Oct 31, 2025.
Key figures: Total number of shares = 100,325,454; Total number of voting rights = 89,406,760. The disclosure follows Article 223-16 of the French financial markets authority general regulation and lists investor and media contact details for further information.
Cellectis (NASDAQ: CLLS) announced two accepted posters for ASH 2025 (Dec 6–9, 2025) in Orlando reporting clinical updates on allogeneic CAR-T programs eti-cel (UCART20x22) and lasme-cel (UCART22).
Preliminary eti-cel Phase 1 results show an 86% ORR and 57% CR at the current dose (n=7); Cellectis plans to present the full Phase 1 dataset, including low-dose IL-2 combination cohorts, in 2026. A preclinical signal suggests low-dose IL-2 may deepen and extend anti-tumor activity.
The lasme-cel poster reports a correlation between alemtuzumab exposure and depth of response in BALLI-01, identifying a threshold exposure linked to higher CR/CRi rates without increased toxicities and supporting planned pivotal Phase 2 enrollment in Q4 2025.
Cellectis (NASDAQ: CLLS) announced it will report its third quarter 2025 financial results for the period ended September 30, 2025 on Friday, November 7, 2025 after the U.S. market close.
The company said the press release will be posted in the Investors section of its website and that no conference call will be held to discuss results; investor inquiries may be directed to investors@cellectis.com.
Cellectis (NASDAQ: CLLS) presented Phase 1 BALLI-01 data for lasme-cel (UCART22) on Oct 16, 2025, showing encouraging activity in heavily pretreated r/r B-ALL patients and a planned pivotal path. Key clinical highlights: Process 2 ORR 69% (P2 n=22), RP2D ORR 83% (n=12) and target Phase 2 population ORR 100% (n=9); CR/CRi 56% in the target population with ~80% MRD-negative responses; median OS 14.8 months in MRD-negative CR/CRi. Safety was described as generally tolerable (CRS 2.5%, ICANS 5%, 8 related SAEs).
Regulatory/commercial: pivotal Phase 2 initiated (first patient expected Q4 2025), BLA targeted 2028, and illustrative 2035 peak gross sales ~$700M (U.S., EU4, UK).
Cellectis (NASDAQ: CLLS) is hosting an R&D Day in New York City on October 16, 2025 to present pipeline progress for its allogeneic cell therapy program.
Leadership and key opinion leaders will present the complete Phase 1 dataset and outline the pivotal Phase 2 trial design and commercial opportunity for lasme-cel (UCART22) in relapsed/refractory B‑ALL. The event runs 08:30–10:30 a.m. ET, is in-person and live via webcast, and a replay will be posted on the company website.
Cellectis (Euronext Growth: CLLS) published its monthly information on share capital and voting rights as of 09/30/2025. The company reports a total number of shares of 100,325,229 and a total number of voting rights of 89,413,272. The disclosure follows Article 223-16 of the General Regulation of the French financial markets authority and lists investor and media contacts for further information.
Cellectis (NASDAQ: CLLS) will present data at the ESGCT Annual Congress in Sevilla on Oct 7-10, 2025 showing advances in non-viral gene therapy and TALE base editors.
Key highlights: a poster on Oct 8, 2025 reports that kilobase-long circular single-stranded DNA (CssDNA) enabled high gene insertion rates in viable HSPCs and greater engraftment and maintenance of edits in a murine model versus AAV-edited HSPCs. A second poster on Oct 9, 2025 reports a comprehensive nuclear off-target analysis for TALE base editors (TALEB) in primary T cells with no observed bias toward C-to-T off-targets near CTCF sites, supporting TALEB safety for therapeutic engineering.
Cellectis (CLLS) has released its monthly share capital and voting rights report as of August 31, 2025. The company reported a total of 100,325,229 shares in its capital structure and 89,428,230 voting rights. This disclosure is made in accordance with Article 223-16 of the General Regulation of the French financial markets authority for companies listed on Euronext Growth.
Cellectis (CLLS) has reported its monthly share capital and voting rights information as of July 31, 2025. The company disclosed a total of 100,325,229 shares in its capital structure and 89,428,630 total voting rights. This disclosure is made in accordance with Article 223-16 of the General Regulation of the French financial markets authority for its listing on Euronext Growth.
FAQ
What is the current stock price of Cellectis (CLLS)?
What is the market cap of Cellectis (CLLS)?
